LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 6, 2026
$1,82
· % dari rentang 52 mgg
· di atas terendah
· ke tinggi
$1,11rendah 52m
$2,68tinggi 52m
Kapitalisasi Pasar (MRQ)
$813M
P/E (TTM)
-12.1
EPS (TTM)
$-0.15
Pendapatan (TTM)
$41M
lencana Anda
Rentang 52M
$1–$3
Peringkat Analis
BUY
Target Harga
$5
P/E
-12.1
ROE
-40.2%
Margin Laba Bersih
-147.4%
Strip lencana Anda kosong — sematkan metrik di mana saja di halaman ini.
LXRX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
Harga
$1.82
Kapitalisasi Pasar (MRQ)
$813M
P/E (TTM)
-12.1
EPS (TTM)
$-0.15
Pendapatan (TTM)
$41M
ROE (TTM)
-40.2%
D/E Utang/Ekuitas (MRQ)
0.3
Rentang 52M
$1–$3
LXRX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Pemecahan saham
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 21 Mei 2015 | 1-for-7 | Terbalik |
Tentang Lexicon Pharmaceuticals, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of different compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
sektorHealthcare
industriPharmaceuticals
karyawan81
negaraUS
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Pendapatan$50M2016-12-31 → 2025-12-31
EPS$-0.142017-12-31 → 2025-12-31
Arus Kas Bebas$-68M2016-12-31 → 2025-12-31
Margin bersih-147.4%2016-12-31 → 2025-12-31
Valuasi & Rasio
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | LXRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E (TTM) | -12.1rata-rata 5T ≈-4.2 | ≈-4.2 | · | · | |
| P/S (TTM) | 19.6rata-rata 5T ≈1530.9 | ≈1530.9 | 6.6 | Terlalu mahal | |
| P/B (MRQ) | 4.7rata-rata 5T ≈4.1 | ≈4.1 | 3.8 | Terlalu mahal | |
| EV / EBITDA (TTM) | -12.5 | · | · | · | |
| Price / FCF (Harga / FCF) | -9.8rata-rata 5T ≈-5.6 | ≈-5.6 | · | · | |
| Price / Cash Flow (Harga / Arus Kas) | -9.8rata-rata 5T ≈-5.7 | ≈-5.7 | · | · | |
| EV / Pendapatan (TTM) | 16.3 | · | · | · | |
| EV / FCF | -9.2 | · | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 10.6rata-rata 5T ≈6.7 | ≈6.7 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | LXRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Margin Operasi (TTM) | -131.4%rata-rata 5T ≈-23342.3% | ≈-23342.3% | -78.2% | Lemah | |
| Margin EBITDA (TTM) | -130.3%rata-rata 5T ≈-23251.5% | ≈-23251.5% | -59.5% | Lemah | |
| Margin Laba Bersih (TTM) | -147.4%rata-rata 5T ≈-23649.3% | ≈-23649.3% | -23.7% | Lemah | |
| ROA (TTM) | -25.7%rata-rata 5T ≈-58.7% | ≈-58.7% | -34.1% | Tingkat teratas | |
| ROE (TTM) | -40.2%rata-rata 5T ≈-105.9% | ≈-105.9% | 50.0% | Lemah |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | LXRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Utang / Ekuitas (MRQ) | 0.3rata-rata 5T ≈0.6 | ≈0.6 | 0.0 | Utang tinggi | |
| Rasio Lancar (MRQ) | 13.4rata-rata 5T ≈5.2 | ≈5.2 | 4.3 | Likuiditas kuat | |
| Rasio Cepat (MRQ) | 13.1rata-rata 5T ≈5.1 | ≈5.1 | 2.0 | Likuiditas kuat | |
| Utang Jangka Panjang / Ekuitas (MRQ) | 0.3rata-rata 5T ≈0.7 | ≈0.7 | 0.0 | Utang tinggi |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
| Metrik | Tren 5 Tahun | LXRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue YoY (Pendapatan YoY) | 60.2%rata-rata 5T ≈631.2% | ≈631.2% | · | · | |
| Revenue CAGR 3Y (CAGR Pendapatan 3T) | 610.2%rata-rata 5T ≈305.9% | ≈305.9% | · | · | |
| Revenue CAGR 5Y (CAGR Pendapatan 5T) | 15.7% | · | · | · |
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | LXRX | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Asset Turnover (Perputaran Aset) | 0.2rata-rata 5T ≈0.1 | ≈0.1 | 0.4 | Lemah | |
| Inventory Turnover (Perputaran Persediaan) | 1.1rata-rata 5T ≈1.2 | ≈1.2 | 2.1 | Lemah | |
| Receivables Turnover (Perputaran Piutang) | 17.0rata-rata 5T ≈8.3 | ≈8.3 | 3.5 | Tingkat teratas | |
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$614.9K | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
48.2%
Laporan Berikutnya
Nov 13, 2026
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 4, 2026 | $-0.07 | $-0.05 | -36.7% |
| 31 Maret 2026 | Mei 11, 2026 | $0.00 | $-0.04 | 100.0% |
| 31 Des. 2025 | $-0.04 | $-0.07 | 43.2% | |
| 30 Sep. 2025 | $-0.04 | $-0.07 | 40.6% | |
| 30 Juni 2025 | $0.01 | $-0.08 | 112.6% | |
| 31 Maret 2025 | $-0.07 | $-0.10 | 29.6% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.29 | · | · | $0.62 | $0.76 | $1.10 | $1.10 | $-0.25 | $0.49 | $1.50 | · | $0.39 | |
| Revenue / Share | $0.14 | $0.10 | $0.01 | · | $0.00 | $0.22 | $2.76 | · | · | · | · | · | |
| Cash Flow / Share | $-0.19 | $-0.56 | $-0.73 | · | $-0.60 | $-1.29 | $0.97 | · | · | · | · | · | |
| Cash / Share | $0.09 | · | · | $0.24 | $0.43 | $0.89 | $0.34 | $0.76 | $0.58 | $0.45 | · | $0.19 | |
| EPS (TTM) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-0.12 | $-0.12 | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,294,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,570,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | · | · | $-64M | $-55M | $-45M | · | $-50M | · | $-31M | · | $-23M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | · | · | $100M | $99M | $100M | · | $99M | · | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | · | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | · | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | · | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | · | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | · | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | · | · | -21.7% | -15.5% | -16.7% | · | -21.6% | · | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | · | · | -40.8% | -25.1% | -25.7% | · | -35.6% | · | -35.3% | · | -16.7% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | · | · | 7.5 | 11.5 | 15.6 | · | 6.9 | · | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | · | · | 7.2 | 11.2 | 15.3 | · | 6.8 | · | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | · | -17.1 | · | -26.7 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | · | · | 0.1 | 0.4 | 0.0 | · | 0.0 | · | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | · | · | 1.1 | 1.0 | 1.3 | · | 0.9 | · | · | · | · |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.39 | $0.48 | · | $0.33 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.05 | · | $0.04 | $0.08 | · | · | $0.00 | $0.01 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.04 | · | · | · | · | · | · | · | $-0.22 | · | · | · | · | · | · | |
| Cash / Share | $0.09 | $0.09 | · | $0.14 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.15 | $-0.07 | · | $-0.18 | $-0.32 | $-0.50 | · | $-0.75 | $-0.78 | $-0.83 | · | $-0.77 | $-0.69 | · | · | · |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $70M | · | $71M | $58M | $31M | · | $5M | $4M | $2M | · | $531.0K | $408.0K | $126.0K | · | · | |
| Net Income TTM | $-61M | $-26M | · | $-69M | $-121M | $-177M | · | $-216M | $-202M | $-194M | · | $-158M | $-131M | $-110M | · | $-97M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -16.0 | -22.3 | · | -7.5 | -3.0 | -0.9 | · | -2.1 | -2.2 | -2.9 | · | -1.4 | -3.3 | · | · | · | |
| P/S | 25.9 | 9.5 | · | 7.0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 22.5 | 7.8 | · | 6.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -6.2% | -4.5% | · | -13.3% | -33.7% | -108.7% | · | -47.8% | -46.4% | -34.6% | · | -70.6% | -30.1% | · | · | · |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | $50M | $31M | $1M | $139.0K | $298.0K |
| Margin Operasi % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Laba Bersih | $-50M | $-200M | $-177M | $-102M | $-88M |
| EPS Dilusian | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utang / Ekuitas | 0.5 | 0.7 | 1.1 | · | 0.0 |
| Rasio Lancar | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Rasio Cepat | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Arus Kas Bebas | $-68M | $-180M | $-162M | $-90M | $-88M |
Pemilik institusional (13F) 167 pengaju · $890.0M total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Pemegang
167
Nilai yang dipegang
$890.0M
Posisi baru
43
Posisi yang keluar
27
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 43 (+9 vs Kuartal sebelumnya) | 27 (+14 vs Kuartal sebelumnya) | 39 (-5 vs Kuartal sebelumnya) | 38 (+14 vs Kuartal sebelumnya) | +42.4M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| Artal Group S.A. | $420.374.549 | 175.156.062 | 47,23% | Saham |
| FMR LLC | $124.276.907 | 51.782.045 | 13,96% | Saham |
| Siren, L.L.C. | $106.328.443 | 44.303.518 | 11,95% | Saham |
| Sessa Capital IM, L.P. | $45.506.006 | 18.960.836 | 5,11% | Saham |
| BlackRock, Inc. | $41.636.978 | 17.348.741 | 4,68% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $23.762.899 | 9.901.208 | 2,67% | Saham |
| Point72 Asset Management, L.P. | $19.803.180 | 8.251.325 | 2,23% | Saham |
| GEODE CAPITAL MANAGEMENT, LLC | $14.989.739 | 6.244.372 | 1,68% | Saham |
| STATE STREET CORP | $11.802.646 | 4.917.769 | 1,33% | Saham |
| VANGUARD GROUP INC | $11.047.532 | 9.606.549 | 1,24% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5.658.598 | 2.357.749 | 0,64% | Saham |
| NORTHERN TRUST CORP | $4.724.686 | 1.968.619 | 0,53% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.696.260 | 1.956.775 | 0,53% | Saham |
| VANGUARD FIDUCIARY TRUST CO | $3.922.970 | 1.634.571 | 0,44% | Saham |
| CITADEL ADVISORS LLC | $3.842.837 | 1.601.182 | 0,43% | Saham |
| CIBC Private Wealth Group LLC | $3.240.347 | 2.400.257 | 0,36% | Saham |
| Ishara Investments LP | $3.050.400 | 1.271.000 | 0,34% | Saham |
| MILLENNIUM MANAGEMENT LLC | $2.722.150 | 1.134.229 | 0,31% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $2.704.800 | 1.127.000 | 0,30% | Saham |
| MACKENZIE FINANCIAL CORP | $2.312.050 | 963.354 | 0,26% | Saham |
| ADAR1 Capital Management, LLC | $1.800.000 | 750.000 | 0,20% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.672.262 | 696.776 | 0,19% | Saham |
| UBS Group AG | $1.643.312 | 684.713 | 0,18% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.604.400 | 668.500 | 0,18% | Opsi beli |
| TWO SIGMA INVESTMENTS, LP | $1.544.266 | 643.444 | 0,17% | Saham |
| Nuveen, LLC | $1.407.994 | 586.664 | 0,16% | Saham |
| JANE STREET GROUP, LLC | $1.398.960 | 582.900 | 0,16% | Opsi beli |
| Bank of New York Mellon Corp | $1.364.893 | 568.706 | 0,15% | Saham |
| Invesco Ltd. | $1.219.370 | 508.071 | 0,14% | Saham |
| GOLDMAN SACHS GROUP INC | $1.165.310 | 485.546 | 0,13% | Saham |
| Compagnie Lombard Odier SCmA | $1.152.000 | 480.000 | 0,13% | Saham |
| BANK OF AMERICA CORP /DE/ | $1.011.117 | 421.299 | 0,11% | Saham |
| BARCLAYS PLC | $929.960 | 387.483 | 0,10% | Saham |
| CITADEL ADVISORS LLC | $886.320 | 369.300 | 0,10% | Opsi beli |
| XTX Topco Ltd | $858.905 | 357.877 | 0,10% | Saham |
| CANADA PENSION PLAN INVESTMENT BOARD | $618.960 | 257.900 | 0,07% | Saham |
| RHUMBLINE ADVISERS | $616.523 | 256.885 | 0,07% | Saham |
| DEUTSCHE BANK AG\ | $594.068 | 247.528 | 0,07% | Saham |
| WELLS FARGO & COMPANY/MN | $553.128 | 230.470 | 0,06% | Saham |
| WELLINGTON MANAGEMENT GROUP LLP | $431.280 | 179.700 | 0,05% | Saham |
| CITIGROUP INC | $420.492 | 175.205 | 0,05% | Saham |
| GROUP ONE TRADING LLC | $420.031 | 175.013 | 0,05% | Saham |
| Virtus Investment Advisers, LLC | $408.996 | 170.415 | 0,05% | Saham |
| Headlands Technologies LLC | $401.275 | 167.198 | 0,05% | Saham |
| Ikarian Capital, LLC | $395.218 | 164.674 | 0,04% | Saham |
| Quarry LP | $374.846 | 156.186 | 0,04% | Saham |
| MetLife Investment Management, LLC | $351.384 | 146.410 | 0,04% | Saham |
| MORGAN STANLEY | $318.964 | 132.902 | 0,04% | Saham |
| PANAGORA ASSET MANAGEMENT INC | $316.901 | 132.042 | 0,04% | Saham |
| JPMORGAN CHASE & CO | $289.975 | 109.839 | 0,03% | Saham |
Aktivis & pemilik 5%+ 11 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 pengajuan | 8 Mei 2026 | 39,40% | Amandemen | · | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 pengajuan | 9 Des. 2024 | · | Pengajuan awal | · | SEC |
| 24 Feb. 2012 | · | Pengajuan awal | · | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 Des. 2011 | · | Pengajuan awal | · | SEC |
| 14 Nov. 2011 | · | Pengajuan awal | · | SEC | |
| 15 Agu 2011 | · | Pengajuan awal | · | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 Maret 2010 | · | Pengajuan awal | Struktur modal | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 pengajuan | 5 Agu 2005 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 8 Agu 2003 | · | Pengajuan awal | · | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 18 Juli 2003 | · | Pengajuan awal | Investasi pasif | SEC |
| Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan | 19 Maret 2003 | · | Pengajuan awal | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 49 orang dalam · 32 pejabat · 19 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 Feb. 2026 M | 298.432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 Feb. 2024 M | 1.098.068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 Feb. 2014 M | 1.021.329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 Feb. 2026 M | 105.356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2 Juni 2009 A | · | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 7 Feb. 2008 A | 50.200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 8 Juli 2024 A | 324.214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 Feb. 2026 M | 31.264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 Feb. 2026 M | 150.132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 Feb. 2026 M | 277.945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 Feb. 2026 M | 323.430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 Feb. 2026 M | 93.869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 Feb. 2026 M | 428.802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 Feb. 2025 M | 76.368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 Feb. 2025 M | 339.104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 Feb. 2025 A | · | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 Feb. 2024 M | 162.672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 8 Feb. 2024 A | · | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 Feb. 2023 M | 53.136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 Maret 2021 M | 71.766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 April 2020 F | 55.584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 April 2020 F | 85.719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2 Maret 2015 M | 8.235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 Feb. 2014 M | 278.703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 Feb. 2010 A | · | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 Feb. 2010 A | 27.306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 7 Feb. 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 7 Feb. 2008 A | 10.200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 7 Feb. 2008 A | · | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 Feb. 2007 A | · | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 Feb. 2004 M | 15.000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 Jan. 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Direktur | 3 Juni 2026 M | 89.312 | 0 | 0 | $0 |
| Diane E. Sullivan | Direktur | 3 Juni 2026 M | 126.122 | 0 | 0 | $0 |
| Judith L Swain | Direktur | 3 Juni 2026 M | 174.486 | 0 | 0 | $0 |
| Amouyal Philippe | Direktur | 3 Juni 2026 M | 374.486 | 0 | 0 | $0 |
| Sam L Barker | Direktur | 3 Juni 2026 M | 213.771 | 0 | 0 | $0 |
| Christopher J Sobecki | Direktur | 3 Juni 2026 M | 293.177 | 0 | 0 | $0 |
| Raymond Debbane | Direktur | 3 Juni 2026 M | 1.995.498 | 7 | 0 | $723.048 |
| Robert J Lefkowitz MD | Direktur | 13 Mei 2024 A | 48.364 | 0 | 0 | $0 |
| Frank Palantoni | Direktur | 21 Mei 2023 M | 40.332 | 0 | 0 | $0 |
| Alan S Nies | Direktur | 21 Mei 2023 M | 41.046 | 0 | 0 | $0 |
| Invus C.V. | Direktur | 31 Des. 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Direktur | 24 April 2009 A | · | 0 | 0 | $0 |
| Clayton Stuart Rose | Direktur | 26 Juni 2007 P | 25.000 | 0 | 0 | $0 |
| Barry Mills | Direktur | 26 April 2007 A | 25.000 | 0 | 0 | $0 |
| Patricia M Cloherty | Direktur | 27 April 2006 A | · | 0 | 0 | $0 |
| Thomas C Caskey | Direktur | 13 Okt. 2005 P | 6.300 | 0 | 0 | $0 |
| Praveen Tyle | · | 28 Feb. 2021 M | 120.791 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 16 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,81% | 161.882 NS | 31 Juli 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0,45% | 40.310 NS | 31 Juli 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,43% | 53.319 SH | 1 Okt. 2026 | Harian |
| IWC · iShares Trust | 0,12% | 842.323 SH | 11 Sep. 2026 | Harian |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 266.401 SH | 19 Agu 2026 | Harian |
| IWO · iShares Trust | 0,03% | 2.343.443 SH | 11 Sep. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1.432.882 SH | 19 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,02% | 118.391 NS | 31 Juli 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 260.485 SH | 30 Sep. 2026 | Harian |
| IWM · iShares Trust | 0,02% | 6.319.224 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2.594.934 SH | 19 Agu 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,01% | 637.561 SH | 19 Agu 2026 | Harian |
| WSML · iShares Trust | 0,01% | 17.992 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 85.389 SH | 3 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 7.083.651 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 20.905 SH | 19 Agu 2026 | Harian |
LXRX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
peringkat · 11 analis
BELI
Target median
$4.55
+150,0%
3 27,3%
Beli Kuat
5 45,5%
Beli
3 27,3%
Tahan
0 0,0%
Jual
0 0,0%
Jual Kuat
Target Harga 12 Bulan
6 analis · 2026-09-30Target rata-rata $4.55 +149,8%
← Di bawah semua target
Harga saat ini $1.82
Rendah$2.00
Rata-rata$4.55
Tinggi$8.00
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| APMD | · | · | · | · | · | · |
| SGP | · | · | · | · | 50.0% | · |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Sumber: SEC 10-Q diajukan Agu 6, 2026